Back to Report Store Home

Global Cancer Supportive Care Therapeutics Market to 2022 – Patent Expirations Create Opportunities for Biosimilars in the Chemotherapy Induced Anemia and Neutropenia Markets

  • Published: Mar-2017
  • Report Code: GBIHC434MR
  • Report Format: pdf

Description

Table of Contents

1 Table of Contents 5

1.1 List of Tables 7

1.2 List of Figures 7

2 Introduction 10

2.1 Therapy Area Introduction 10

2.2 Epidemiology 10

2.2.1 Cancer Pain 10

2.2.2 Chemotherapy Side Effects 11

2.2.3 Oral Mucositis 11

2.3 Pathophysiology 11

2.3.1 Bone Metastasis 11

2.3.2 Oral mucositis 12

2.3.3 Cancer Pain 12

2.3.4 Chemotherapy-Induced Nausea and Vomiting 12

2.3.5 Chemotherapy-Induced Anemia 13

2.3.6 Chemotherapy-Induced Neutropenia 13

2.4 Etiology 13

2.5 Symptoms 14

2.6 Diagnosis and Grading 14

2.7 Treatment 17

2.7.1 Chemotherapy-Induced Nausea and Vomiting 17

2.7.2 Chemotherapy-Induced Neutropenia 18

2.7.3 Chemotherapy-Induced Anemia 18

2.7.4 Cancer Pain 19

2.7.5 Bone Metastases 19

2.7.6 Oral Mucositis 19

3 Key Marketed Products 21

3.1 Overview 21

3.2 Neulasta (pegfilgrastim) – Amgen 22

3.3 Xgeva (denosumab) – Amgen 23

3.4 Aranesp/Nesp (darbepoetin alfa) – Amgen/Kyowa Hakko Kirin 24

3.5 Xofigo (radium Ra 223 dichloride) – Bayer 26

3.6 Nucynta (tapentadol hydrochloride) – Depomed 27

3.7 Epogen/Procrit (epoetin alfa) – Amgen/Johnson & Johnson 29

3.8 Neupogen (Filgrastim) – Amgen 30

3.9 Aloxi (palonosetron hydrochloride) – Eisai/Otsuka Holdings Co Ltd. 32

3.10 Conclusion 33

4 Pipeline Landscape Assessment 35

4.1 Overview 35

4.2 Pipeline Development Landscape 35

4.3 Molecular Targets in the Pipeline 38

4.4 Clinical Trials 40

4.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target 41

4.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target 45

4.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target 49

4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target 53

4.4.5 Conclusion 57

4.5 Assessment of Key Pipeline Products 57

4.5.1 Tanezumab – Pfizer and Eli Lilly 57

4.5.2 Rolontis (Eflapegrastim) – Spectrum Pharmaceuticals 59

4.5.3 Conclusion 60

4.6 Multi-scenario Market Forecast to 2022 61

4.6.1 Overall Market Size 61

4.7 Generic Penetration 63

5 Revenue Forecast by Molecular Target 66

5.1 Cytokine Receptors 66

5.2 G Protein-Coupled Receptors 67

5.3 Company Analysis and Positioning 68

5.3.1 Revenue and Market Share Analysis by Company 70

5.3.2 Amgen – Can it Retain its Market-Leading Position Despite Patent Expiries for Key Products? 74

5.3.3 Bayer – Will Revenue from Xofigo Continue to Increase during the Forecast Period? 75

5.3.4 Heron Therapeutics – Will New Approvals Allow a Small Company to Obtain a Significant Market Share? 76

5.3.5 Insys Therapeutics – Can Reformulations Be Commercially Successful if Generics are Available? 77

5.3.6 Kyowa Hakko Kirin – How will the Japanese Cancer Supportive Care Market React to Patent Expiries for Some of the Therapy Area’s Most Successful Drugs? 78

5.3.7 Daiichi Sankyo – Will Revenue from Injectafer and Ranmark Continue to Increase during the Forecast Period? 79

6 Company Landscape 81

6.1 Marketed and Pipeline Portfolio Analysis 81

7 Strategic Consolidations 84

7.1 Licensing Deals 84

7.1.1 Deals by Region, Year and Value 84

7.1.2 Deals by Indication, Stage of Development and Value 85

7.1.3 Deals by Molecule Type, Molecular Target and Value 87

7.1.4 Table for Licensing Deals with a Disclosed Value 89

7.2 Co-development Deals 92

7.2.1 Deals by Region, Year and Value 92

7.2.2 Deals by Indication, Stage of Development and Value 93

7.2.3 Deals by Molecule Type, Mechanism of Action and Value 95

7.2.4 Table for Co-development Deals with a Disclosed Value. 97

8 Appendix 98

8.1 Bibliography 98

8.2 All Pipeline Drugs by Phase of Development 102

8.2.1 Discovery 102

8.2.2 Preclinical 104

8.2.3 IND/CTA-filed 113

8.2.4 Phase I 113

8.2.5 Phase II 115

8.2.6 Phase III 118

8.2.7 Pre-registration 120

8.2.8 Unknown 121

8.3 Abbreviations 122

8.4 Disease List 123

8.5 Methodology 123

8.5.1 Coverage 123

8.5.2 Secondary Research 124

8.5.3 Market Size and Revenue Forecasts 124

8.5.4 Pipeline Analysis 124

8.5.5 Competitive Landscape 125

8.6 Contact Us 125

8.7 Disclaimer 125

 
      captcha refresh

I have read and accept terms and conditions and privacy policy

Cancel
License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$4995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$9990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$14985
Email to a colleague Request Sample Pages Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5817
Or click here to contact us
Secure Payments
Cards